<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588987</url>
  </required_header>
  <id_info>
    <org_study_id>MA-GBM-II-001</org_study_id>
    <nct_id>NCT04588987</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma</brief_title>
  <official_title>A Study to Evaluate the Safety and Efficiency of Using the Neoadjuvant Therapy With Carilizumab and Apatinib in Patients With Recurrent High-Grade Glioma ：A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary&#xD;
      intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the&#xD;
      prognosis of glioma patients is still very poor. The study aim to Evaluate the Safety and&#xD;
      efficiency of Using the neoadjuvant therapy with Carilizumab and Apatinib in patients with&#xD;
      Recurrent High-Grade Glioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time from enrollment to the dates of death from any cause or last follow up reported between date of first patient enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Carilizumab</condition>
  <condition>Apatinib</condition>
  <condition>Recurrent High-Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1</intervention_name>
    <description>Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG</description>
    <arm_group_label>Adjuvant group</arm_group_label>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <other_name>apatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Age 18-70 years old, both male and female.&#xD;
&#xD;
          3. After biopsy or surgery, the postoperative pathological diagnosis was WHO III-IV&#xD;
             glioma.&#xD;
&#xD;
          4. Patients in whom surgery can be safely delayed for a minimum period of 2 weeks&#xD;
             following the administration of the first dose of nivolumab, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          5. KPS score ≥60；&#xD;
&#xD;
          6. Life expectancy &gt;12 weeks.&#xD;
&#xD;
          7. Adequate organ function defined by:&#xD;
&#xD;
               1. HGB≥110g/L；&#xD;
&#xD;
               2. WBC≥3.0×109/L；NEUT≥1.5×109/L；&#xD;
&#xD;
               3. PLT ≥75×109/L；&#xD;
&#xD;
               1. BIL≤1.5ULN；&#xD;
&#xD;
               2. ALT and AST≤2.0×ULN；&#xD;
&#xD;
               3. creatinine &lt; 1.5 x ULN or estimated creatinine clearance≥50ml/min（using the&#xD;
                  Cockcroft-Gault formula）&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of extracranial disease.&#xD;
&#xD;
          2. Previous treatment with a PD-1, PDL-1 or CTLA-4，VEGFR targeted therapy.&#xD;
&#xD;
          3. Pregnant or breastfeeding patients.&#xD;
&#xD;
          4. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS). Routine testing is not required.&#xD;
&#xD;
          5. Positive tests for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV RNA) indicating active or chronic infection.&#xD;
&#xD;
          6. History of allergy to study drug components or of severe hypersensitivity reactions to&#xD;
             any monoclonal antibodies.&#xD;
&#xD;
          7. Known drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Zhong ping, PHD</last_name>
    <phone>020-8734009</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ke Chao, PHD</last_name>
    <email>kechao@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer center of Sun Yat sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Chao, PHD</last_name>
      <email>kechao@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ju xue, PHD</last_name>
      <email>yangqy@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ke Chao kechao@sysucc.org.cn, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Zhongping chenzhp@sysucc.org.cn, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

